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Abstract—Reversible inhibitors are associated with fewer side eﬀects than covalently binding ones and are, therefore, advantageous
for treatment of conditions involving endogenous enzymes. Transition state analogue structures provide one design paradigm for
such inhibitors; this paradigm seeks to exploit the capability of an enzyme active site to stabilise a transition state or associated
intermediate. In contrast, structures that retain the functionality, and scissile bond of the substrate, can also act as reversible
inhibitors; these are referred to here as substrate variants to distinguish them from substrate analogues. Their mode of inhibition
depends on destabilisation of a reaction-path transition state or states. As the mode of destabilisation can be quite varied the scope
to exploit substrate variants as reversible inhibitors is substantial. The two design paradigms are contrasted here and the case of
substrate variants is delineated with a well-deﬁned set of structures. These include the naturally occurring polypeptides BPTI (an
inhibitor of a serine-based protease) and cathepsin propeptides (inhibitors of cysteine-based proteases) as well as the synthetic small-
molecules cilastatin (an amide inhibitor of a zinc-based protease) and substituted mono- and tripeptides as inhibitors of cathepsins
K and L.
 2004 Elsevier Ltd. All rights reserved.1. Introduction
The design of enzyme inhibitors as structural analogues
of intermediates, and as apparent analogues of transition
states, is well established. The analogue design paradigm
is based on replacing the main substrate functional group
so as to entirely alter the reacting system, for example,
substitution of a scissile bond by a nonscissile one. This
allows incorporation of features into a stable molecule
that mimic primary transition–state interactions of the
natural substrate and the enzyme active site.1 This ap-
proach, thus, seeks to exploit the capability of an enzyme
active site to stabilise a transition state structure so that
the stable transition state analogue is bound with a far
higher aﬃnity than the normal substrate. A generalised
energy proﬁle of this mode of noncovalent inhibition is
shown schematically in Figure 1(a): the substrate proﬁle
is representative of scission of an ester or an amide
involving the formation and breakdown of a tetrahedral
intermediate. The proﬁles are shown as intersecting
(orthogonal for simplicity) as the ‘stable’ inhibitor can-
not undergo a reaction comparable to that of the sub-* Tel.: +353-61-202162; fax: +353-61-202568; e-mail: timothy.smyth@
ul.ie
0968-0896/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2004.05.041strate; the inhibitor proﬁle shown represents some
possible reaction path but one with a very high activation
energy. The structural connection between the two pro-
ﬁles––the intermediate on the substrate proﬁle and the
stable analogue structure on the inhibitor proﬁle (EÆA)––
is shown by the dashed line.
In contrast to the above, structures that retain the
functionality and the scissile bond of the substrate can
also act as potent, noncovalent, reversible inhibitors.
The term substrate variant is used here to identify
R0C(O)NHR
00
as a variant of RC(O)NHR (the sub-
strate) and to distinguish it from RC(O)CH2R, which is
an analogue of the substrate (see Table 1). A generalised
energy proﬁle that shows substrate variants acting as
inhibitors is given in Figure 1(b). The proﬁles of the
substrate and variant are shown as being parallel as both
structures can, potentially, undergo the same type of
transformation. Transfer of the energy surface for a
substrate from an aqueous to an enzyme phase results in
greater stabilisation of the transition state over that of
the substrate (the default scenario for catalysis), whilst
for the closely related structure Sv the corresponding
transfer results in greater stabilisation of Sv over
its cognate transition state (there is conservation of
interaction energy when integrated over the energy
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Figure 1. Schematic representation of the relationship between the energy proﬁles of (a) a substrate (S) versus that of a structure that is an analogue
(A) of an intermediate or transition state as an inhibitor and (b) a substrate (S) versus that of a substrate variant (Sv) as an inhibitor.
Table 1. Protease inhibitor characteristics of substrate variants, transition state analogues and substrate analogues
Substrate variants Transition state analogues Substrate analogues
Functionality presented at
the active site
Amide bond of unaltered reactivity
compared with normal substrate
Various nonreactive groups Carbonyl (or related) group with
enhanced reactivity over normal
substrate
Design paradigm––binding
versus reactivity
Binding exclusively; normal reaction
pathway is destabilised within the
active site; noncovalent interaction
primarily
Binding exclusively; stable struc-
ture––possible reaction pathways are
inherently destabilised; noncovalent
interaction
Binding and reactivity;a mechanism-
based covalent interaction
Examples Endogenous inhibitors: BPTI and
related structures; various propep-
tides
Endogenous inhibitors: pepstatin.b Exogenous inhibitors: b-lactams
(both naturally occuring and syn-
thetic); c-lactams with an EWG on
nitrogen;c lactones; ketones; alde-
hydes etc.
Exogeneous inhibitors: cilastatin;
peptides A and B (see Chart 2 here)
Exogenous inhibitors: phosphinates;
statines, norstatine;b etc.
a The relevance of reactivity in acylation-type inhibitors has been reviewed: Ref. 21.
bRef. 22; for comments on these as strict transition state analogues see: Ref. 23.
c Ref. 24.
4082 T. P. Smyth / Bioorg. Med. Chem. 12 (2004) 4081–4088surface as enzymes provide an alternative medium for a
reaction but are not net energy producers). It follows
that Sv will act as a competitive, reversible inhibitor in a
reaction where S is the substrate. The eﬀectiveness of Sv
as an inhibitor, thus, depends on destabilisation of a
reaction-path transition state or states (large DG#Sv)
combined with tighter binding of the variant (EÆSv)
compared with the normal substrate. This mode of
inhibition is less well established compared with that of
transition state analogues and it is instructive to delin-
eate the variety of inhibitory modes of a well-deﬁned set
of such structures. The examples dealt with here include
the naturally occurring polypeptides BPTI (an inhibitor
of a serine-based protease) and cathepsin propeptides
(inhibitors of cysteine-based proteases) as well as the
synthetic small-molecules cilastatin (an amide inhibitor
of a zinc-based protease) and substituted mono- and
tripeptides as inhibitors of cathepsins K and L. The
mode of destabilisation is distinct in each case, which
indicates that the scope to exploit substrate variants as
reversible inhibitors is substantial.2. Discussion
Base-catalysed hydrolysis of an amide bond occurs in
two steps involving formation and fragmentation of theintermediate resulting from hydroxide addition to the
amide carbonyl (Scheme 1). The steps of hydroxide
addition and amine departure are viewed as proceeding
along a B€urgi–Dunitz trajectory of nucleophile/nucleo-
fuge addition/release to/from the carbonyl group/cog-
nate intermediate.2 The reaction ensemble wherein the
nucleophile/nucleofuge is appropriately juxtaposed, in
terms of separation (2.7–3.0A) and angle of approach/
departure (a  103 15), to initiate bond formation/
complete bond scission, has been labelled as a near-at-
tack conformer3 (NAC-1 and NAC-2 in Scheme 1). The
same features apply to the general base-catalysed addi-
tion of a serine alkoxide or cysteine thiolate (for these
proteases a second step is required to eﬀect hydrolysis of
the acylated active site). Bond formation and scission
involves heavy-atom displacement along speciﬁc reac-
tion coordinates and these processes dynamically change
the values of nonbonded interactions between substrate
components and active-site residues. These interactions,
which are acutely (and anharmonically) dependent on
internuclear separation, play a central role in substrate
binding and in transition state stabilisation. In addition
to these heavy atom displacements, proton transfer from
an appropriately juxtaposed acid to the nucleofugic
nitrogen of the tetrahedral intermediate is essential
(Scheme 1). The structural requirements of substrate
speciﬁcity and eﬃciency of catalysis must involve a
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with the extent and dynamics of their elasticity.4 This
provides a basis for understanding features that are
common to the inhibitory mode of action of the very
distinct structures, cilastatin, BPTI, cathepsin propep-
tides and small-molecule inhibitors of cathepsins.2.1. Cilastatin
Cilastatin (Chart 1) was developed empirically as a
reversible inhibitor of membrane dipeptidase (MDP),
which is a zinc-based mammalian enzyme. This enzyme
catalyses hydrolysis of the cysteinylglycine dipeptide end
group of leukotriene-D4 (LTD4, Chart 1), amongst
other metabolic processes, and it also cleaves the b-
lactam ring of the antibiotic imipenem. This latter
problem is overcome by co-administration of cilastatin
with imipenem.5 A detailed analysis of the X-ray
structure of MDP with cilastatin bound at its active site6
together with the results of docking studies of substrate
molecules, led to the depiction of its mode of action as
(one form of) a substrate variant.7NH
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Chart 1. Substrate and inhibitor structures of membrane dipeptidase
(MDP). The scissile amide bond is indicated (arrow).The active site of MDP is a rectangular pocket on the
protein surface measuring approximately 10A
(length) · 6A (width) · 6A (depth) and its substrate
speciﬁcity is, largely, deﬁned by these dimensions.6 Key
internuclear separations of cilastatin bound at the active
site are shown in Figure 2. The view is from the open top
face of the active site towards the base, which contains
two zinc ions and a water molecule; relevant internu-
clear separations of these are given in Figure 3. The
carboxylate of Asp288 (not shown) is ideally positioned
to provide general-base/acid catalysis of proton relay
from the water molecule and subsequent transfer to the
nucleofugic nitrogen of cilastatin. The zinc-bound water
is in a perfect NAC for formation of an addition inter-
mediate: the oxygen atom is at 2.82A from the amide
carbonyl and forms an angle, a, of 102.9. In addition,
the imidazole ring of His152 is positioned so as to form
a good hydrogen bond with the oxyanion of this inter-
mediate. These features are ideally suited for addition of
the hydroxide ion to generate an addition intermedi-
ate––there is no impediment to progress along this
reaction coordinate. The reaction coordinate for
departure of the amine leaving group from this inter-
mediate is along the Tyr68-to-Tyr252 axis (Fig. 2). The
dimethylcyclopropyl group and the alkyl side chain of
cilastatin lie along this axis and clearly buttress the side
chains of these peripheral tyrosines. At a separation of
3.52A the interaction energy of a cyclopropyl carbon
with that of Tyr68 is only very marginally stabilising,
whereas, at a separation of 3.90A the interaction energy
of an alkyl side-chain carbon with that of Tyr252 is just
about optimal (see Fig. 4 and associated equation8).
Overall, these interactions contribute to the binding of
cilastatin as a NAC at the active site; note that Ki for
cilastatin is 0.1 lM,5b which contrasts with a Km value of
1mM for a typical (synthetic) substrate––glycyldehydro-
phenylalanine (Gly-D-Phe; Chart 1).9 Departure of the
amine leaving group from the intermediate derived from
cilastatin requires an internuclear separation of the
amine nitrogen and the carbonyl carbon of 2.7–3.0A,
that is the separation occurring in the product NAC
(NAC-2 in Scheme 1). As the amide bond length in
cilastatin is 1.38A a heavy-atom displacement of 1.32–
1.62A is necessary. Such a displacement would place the
dimethylcyclopropyl and alkyl end group of cilastatin at
internuclear separations to Tyr68 and Tyr252, respec-
tively, that would be highly destabilising. Reducing R
Figure 3. Heavy-atom separations (A) of cilastatin with Zn2þ (black)
and water/hydroxide (red). A polar hydrogen only has been added to
cilastatin here.
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Figure 4. Potential energy E (J/mol) versus internuclear separation R
for C/C nonbonded interaction.8
Figure 2. Heavy-atom separations (A) of cilastatin with MDP active-site residues (PDB code 1ITU).6 Hydrogen bonds to cilastatin are shown in red
and nonpolar interactions in green; other selected distances are shown in black. Note that the tyrosine in the top left here, Y365-B, is part of the
(disulﬁde) linked second monomer unit of MDP.
4084 T. P. Smyth / Bioorg. Med. Chem. 12 (2004) 4081–4088for one C/C nonbonded atom pair from the Req value of
3.89 to 2.57A (a reduction of 1.32A) would give an
interaction energy of +21.90 kJ/mol whilst reduction by
1.62 to 2.27A would give a value of +68.13 kJ/mol (see
Fig. 4 and associated equation).10 Some of the dynamic
motions of enzyme residues––depending on their time
scale11––can attenuate these kinds of interactions,however, there must be a limit on the capacity of the
active site to readily expand beyond that for which it has
evolved in terms of its substrate set, in particular, for an
enzyme that has a stringent substrate speciﬁcity.4 This
appears to be the case with MDP. The active site
dimensions in native and cilastatin-bound MDP are very
similar; this and other data on substrate speciﬁcity point
to a limited capability of the MDP active site to readily
expand much beyond the dimensions of the native
protein7 (the tight ﬁt of cilastatin along the Tyr68-to-
Tyr252 axis may serve to restrain antisymmetric motion
(expansion) of the active site along this axis4b). Based on
the internuclear separations available from the X-ray
structure of cilastatin-bound MDP (Fig. 2) it was esti-
mated that an expansion of 0.52A could be accommo-
dated,7 giving an internuclear separation of the amine
nitrogen and carbonyl carbon of 1.90A, whereas,
attaining the minimum required separation of 2.7A
would require a signiﬁcant further energy input. In
contrast, with the substrates LTD4 and Gly-D-Phe this
minimum separation could be readily accommodated
within the active site dimensions. Thus, docking of these
showed that the scissile amide bond of each could bind
in an NAC orientation at the active site in a manner
essentially identical to that observed for cilastatin. The
docking studies showed that there is over 1A more
available for displacement of the amine leaving group
along the horizontal axis for each of these compared to
that available to cilastatin.7 An increase of 1.52A
between the amine nitrogen and carbonyl carbon of
LTD4 (giving a total separation of approximately
2.90A) occurring uniquely by displacement of the glycl
moiety toward Tyr252 would still result in a favourable
interaction energy of the corresponding nonbonded
carbons. Whatever the degree of ﬂexibility of the
peripheral residues that facilitates this displacement for
a normal substrate, it is apparent that this is not suﬃ-
cient to accommodate the same process for cilastatin.
T. P. Smyth / Bioorg. Med. Chem. 12 (2004) 4081–4088 4085The key features of cilastatin as a substrate variant can
be summarised as follows: it binds using the same
noncovalent interactions as the primary functional
group of the substrate, but in addition, its substituent
array buttresses residues on the periphery of the active
site at internuclear separations that are close to the limit
for favourable interaction energies––it is tight ﬁtting and
by default tight binding; this arrangement impedes
heavy-atom displacement along a key reaction coordi-
nate axis thereby destabilising the associated transition
state. It ﬁts the proﬁle shown for a substrate variant (Sv)
in Figure 1(b) wherein the step of high activation energy
is associated with breakdown of the tetrahedral inter-
mediate.2.2. BPTI
BPTI is a naturally occurring 58 unit polypeptide that is
a potent (Ki ¼ 1013 M), endogenous, inhibitor of tryp-
sin––a serine-based protease.12 Enzyme-catalysed con-
version to products does not occur––the rate of
hydrolysis of BPTI by trypsin (kcat ¼ 8:7 1010 s1) is
slower than that of a typical substrate by a factor of 1011.
Crystal structure data show that BPTI––and a number of
related protease inhibitors12b–e––bind at the active site
with the scissile amide bond positioned in a catalytically
competent (NAC), substrate-like manner. A typical
example is given in Figure 5:12f this shows an internuclear
separation of 2.78A between the side chain oxygen of the
active-site Ser195 to the carbon of the scissile amide
carbonyl (at an angle a ¼ 89:4) and, in addition, Gly193
and Ser195 are suitably positioned to provide hydrogen-
bond stabilisation of the tetrahedral intermediate derived
from addition of the Ser195 alkoxide to the Lys15-BPTI
carbonyl. His57 is suitably placed to provide general-
base/acid catalysis of proton relay from Ser195 and
subsequent transfer to the nucleofugic nitrogen of Ala16.
A detailed analysis of the interaction of BPTI, and of aFigure 5. (i) BPTI (in green except for Lys15-Ala16) bound to trypsin (PDB co
site serine highlighted. (ii) Internuclear separations (A) of active-site compone
Hydrogen bonding interactions are shown in red.substrate, with trypsin has been carried out by Per€akyl€a
and Kollman using a quantum mechanical-free energy
(QM-FE) approach together with molecular dynamic
simulations.13a These calculations showed that the
intermediate generated by addition of the alkoxide of
Ser195 to Lys15-BPTI, and the transition states associ-
ated with its formation and fragmentation, are destabi-
lised with respect to the corresponding entities generated
from a substrate structure. The exclusion of water by
BPTI from the active site (Fig. 5 (i)) plays a major role in
this destabilisation as does the less favourable interaction
energies of trypsin and BPTI amino acid residues. On
this basis a decrease in catalytic rate of 106–109 (of a total
reduction of 1011) was accounted for. The remaining
decrease of 105–102 was attributed to restricted diﬀusion
of the cleaved amino moiety, which leads to reformation
of the scissile amide bond in preference to hydrolysis of
the acylated active site (the restricted diﬀusion of the
leaving group is due, partly, to an intramolecular con-
straint as BPTI is crosslinked with disulﬁde bonds).
Progress along the hydrolysis reaction coordinate can
also be impeded by exclusion of water. Thus, the asso-
ciated transition state(s) may be destabilised due to the
absence of solvent water molecules, and/or access of the
required nucleophilic water molecule may be blocked;
this latter process on its own will reduce the rate of the
hydrolytic step irrespective of any destabilisation of the
transition state(s).
The key features of BPTI as a substrate variant can be
summarised as follows: it binds in a catalytically com-
petent (NAC), substrate-like manner; cleavage of the
amide bond to generate the acylated enzyme occurs
slowly as the intermediate and associated transition
states are destabilised within the enzyme environment; re-
ligation of the cleaved amide bond is thermodynamically
favourable, and this occurs more readily than hydrolysis
of the acylated enzyme as water is excluded from the
active site.13 These observations are delineated in thede 3TGI).12f The enzyme is shown as a ribbon diagram with the active-
nts; Lys15 and Ala16 occupy the S1 and S10 binding sites, respectively.
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Figure 6. Schematic energy proﬁle of trypsin-catalysed hydrolysis of a normal polypeptide substrate (S), and with BPTI. Adapted from Ref. 13a.
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occupation of the energy minima––EBPTI and/or Eacyl-
BPTI-NH2––provides equally eﬀective inhibition.
142.3. Cathepsins
Cathepsins are cysteine-based proteases, some of which
have been identiﬁed as important targets for inhibi-
tion.15 The cathepsins are synthesised in an inactive
proenzyme form bearing a 60–100 unit polypeptide (the
propeptide) that is tightly bound (noncovalently) at the
active site; in the case of cathepsin-L the 96 unit pro-
peptide has a Ki value of 0.088 nM.15a It has been
established that the propeptide binds in a reverse-sub-
strate mode, that is the amino-to-carboxy-terminus
alignment is opposite to that of a substrate molecule
and this has implications regarding catalysis of cleavage
of the scissile bond. The amino acid substituents, thatFigure 7. (i) Procathepsin-K (PDB code 1BY8).16a The enzyme is shown as a r
is shown in green except for Thr76-Gly77. (ii) Active-site internuclear sepa
rotamer of the side chain of Cys124. Hydrogen bonding interactions are shoare attached to either side of the scissile amide bond,
occupy the various binding pockets
(. . .S2.S1.S10.S20. . .), and generate favourable interac-
tion energies that contribute to the observed tight
binding.16 Crystal structure data show that, although
the scissile amide bond is held in proximity to the ac-
tive-site cysteine, the reverse-substrate binding pre-
cludes its juxtaposition as a catalytically competent
NAC. The crystal structure of procathepsin-K16a (Fig. 7,
(i) and (ii)) shows the sulfur of the active-site cysteine
(Cys124) at 3.76A from the propeptide carbonyl, Thr76-
p, and at 4.11A from the imidazole ring of His261 (the
general-base/acid). A simple rotation of the cysteine side
chain places the sulfur atom in a more reactant-like
orientation (Fig. 7 (iii)), however, the key discrepancy
remains the remote location of the nucleofugic nitrogen
(#) from the imidazole of His261 that catalyses the
proton relay process. A normal substrate would have its
nucleofugic nitrogen close to the position occupied byibbon diagram with the active-site cysteine highlighted. The propeptide
rations (A) from the crystal structure, and (iii) as (ii) but showing a
wn in red.
T. P. Smyth / Bioorg. Med. Chem. 12 (2004) 4081–4088 4087the labelled carbon atom (*) of the propeptide, which is
appropriate for facile completion of the proton relay.
The imidazole of His261 is not solvent accessible with
the propeptide in place, so a water mediated proton
relay cannot occur (unlike the case of BPTI, water is not
totally excluded from contact with the propeptide resi-
dues at the active site). In the case of the propeptide,
therefore, the transition state leading from the addition
intermediate to the acylated enzyme is destabilised; the
experimental data indicate that the extent of this de-
stabilisation is suﬃcient to preclude scission of the
propeptide.
Recently, the synthetic small molecules A15c and B15d
(Chart 2) were developed as selective, high aﬃnity and
reversible inhibitors of cathepsins K and L, respectively.
X-ray data showed that B was bound as shown in Chart
2, which mirrors the reverse-substrate orientation of the
propeptide on which it was modelled.15d Given that the
speciﬁcity pockets of cathepsins K (PDB code 1BY8)16a
and L (PDB code 1CS8)16b are quite similar, the selec-
tivity shown by A and B is signiﬁcant. These small
molecules, together with their cognate propeptides,
constitute another form of substrate variant as enzyme
inhibitor.3. Conclusion and perspectives
The common inhibitory feature of the diverse structures
presented in the foregoing sections, is the high aﬃnity of
the substrate variant in its ground state for the active site
combined with destabilisation of a key reaction-path
transition state. The mode of this destabilisation is dis-
tinct in each case, which indicates that the scope to ex-Ki(µM)
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H
H
R
N
N
N
R'
O
N
CH3S O
C6H5
O
NH2
NH2
D
H
R' =
R' =
3
H
+ S1
S2
S3
S1'
S2'
O
N
H
R' =
R' =
O
O
H
N
O
NR R'
H
H N
B
A
S2'
S1'
Chart 2. The substituted peptide (A) and tripeptide (B) that act as
reversible inhibitors of cathepsins K and L, respectively.15c;d The
scissile amide bond is indicated (arrow). The binding pockets are
identiﬁed for B from the crystal data,15d whereas, those for A are
assigned here by analogy with B.ploit substrate variants as inhibitors may be substantial.
Reversible inhibitors show fewer side eﬀects compared
to covalently binding inhibitors, whilst, substrate-based
structures can be quite discriminating amongst closely
related members of a family of enzymes (as per A and B
above). These are desirable inhibitor characteristics for
treatment of conditions involving endogenous enzymes.
The explicit design of substrate variants has the poten-
tial to expand the base of such inhibitors. Cilastatin is a
prime functional example with a positive safety and
toxicity record in clinical usage.5b;17 Binding of a suﬃ-
ciently high aﬃnity for therapeutic use is not the pre-
serve of small-molecule transition state analogues or
macromolecular polypeptides, and neither are the
characteristics of bioavailability and stability limited to
nonsubstrate-type structures.15b
Cilastatin and peptide A were developed, largely, on an
empirical basis from a lead structure and, subsequently,
using a relatively small library of structures for optimi-
sation. With tripeptide B, modelling of the propeptide
region and docking studies were key components of the
development strategy; optimisation also required only a
relatively small structure library. The BPTI design par-
adigm may be less readily exploited compared to that
embodied in cilastatin and in the peptides A and B.
Penicillin and related structures provide, however, a
relevant small-molecule parallel. Inhibition of bacterial
(serine-based) peptidases by b-lactams involves their
binding in a substrate-like NAC followed by amide
bond cleavage yielding an acylated enzyme and re-
stricted diﬀusion of the cleaved amino group––this is
covalently linked to the acylated active site. The retained
amino group impedes access by a water molecule,
thereby, retarding hydrolysis of the acylated enzyme.
Although the cleaved amino group may be appropri-
ately juxtaposed18––as a product NAC––to reform the
b-lactam bond, this is not thermodynamically favour-
able and, so, the mode of inhibition is essentially irre-
versible. Formation of a lactam bond has been shown to
occur at an acylated active site, however, to generate
(larger-ring) c-lactams.19a;b In the context of using these
to develop irreversible (covalent) inhibitors of bacterial
peptidases this ﬁnding is negative,19c however, the
c-lactam structure type represents a rudimentary, small-
molecule embodiment of the BPTI design paradigm.
Substrate variants may also have application as inhibi-
tors of rapidly evolving microorganisms or cell lines. A
detailed analysis of the variability of amino acid residues
of the protease enzyme produced by HIV-virus strains
known to be (clinically) resistant to a number of distinct
(reversible) protease inhibitors showed that,20 (i) active-
site residues that had favourable interaction energies
with the substrate were highly conserved (i.e., were
subject to low mutation rates), and (ii) that many
resistant strains showed a single amino acid change
only. Signiﬁcantly, the residue mutated (in the resistant
strain) strongly interacted originally (in the wild type)
with a fragment of an inhibitor structure but only very
weakly, if at all, with the substrate. The clear inference20
was that use of inhibitor structures designed to
maximise interaction with highly conserved active site
4088 T. P. Smyth / Bioorg. Med. Chem. 12 (2004) 4081–4088residues––those involved in substrate binding and
transformation––should reduce the scope for evolution
of resistant strains. Some of the design features of sub-
strate variants described in the preceding sections could
lead to structures that meet these requirements.Acknowledgements
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